"So what happens if Brilacidin is shown to be effective on 15 of the 20 viruses that are being tested and then WHO decides to run Phase 2 studies on the 5 most promising?"
Probably nothing, as in vitro studies don't amount to much, just indications that a Ph1 or maybe even later, a Ph2 could pay off, if someone wants to take a chance funding a new Tamiflu. IPIX does not have the money and has the thinnest track record of getting outside licensing (just AS, right?). I am trying to be realistic. And unlikely the WHO would fund anything unless the Chinese gave the go ahead, see (https://www.theatlantic.com/politics/archive/2020/05/china-global-influence-who-united-states/611227/), and why would they?
That said, of course funding for wide-scoped anti-viral trials of Brilacidin would be great. Just not likely to happen, imo.
If we don't get some kind of promise in the the form of silver lining secondary endpoints on the COVID trial, I think Brilacidin's chances as an antiviral have gone up in smoke. WHO is in government donor pockets...they aren't doing squat with Brilacidin unless Gilead or one of the big boys owns it.
I'm just hoping we can get some turd-tier pharma to put a few million upfront and cover our phase 3 OM for a chance at some real revenues.